Vertex Pharmaceuticals VRTX
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 875320; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 30, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 31, 2025 | Q2 2025Jun 30, 2025 | Q3 2025Sep 30, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 31, 2026 | Q2 2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.8B | $3.0B | $3.1B | $3.2B | $3.0B | $3.3B |
| Operating income | $1.1B | $1.0B | $0.6B | $1.2B | $1.2B | $1.2B | $1.1B | $1.2B |
| Net income | $1.0B | $0.9B | $0.6B | $1.0B | $1.1B | $1.2B | $1.0B | $1.1B |
| Capital spending | $0.1B | $0.1B | $0.0B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| Operating cash flow | $1.4B | $0.6B | $0.8B | $1.1B | $1.2B | $0.5B | $1.4B | $1.1B |
| Free cash flow | $1.3B | $0.5B | $0.8B | $0.9B | $1.1B | $0.3B | $1.3B | $1.0B |
| Capex / operating cash flow | 4.9% | 15.8% | 5.0% | 13.6% | 8.2% | 30.0% | 9.3% | 10.0% |
| Shares outstanding | 257.5M | 256.8M | 256.8M | 256.4M | 253.7M | 254.0M | 253.8M | 253.5M |
| Share count change, y/y | −0.1% | −0.6% | −0.5% | −0.7% | −1.5% | −1.1% | −1.2% | −1.1% |
| Diluted shares (weighted avg.) | 261.0M | — No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 259.5M | 258.9M | 257.6M | — No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 256.3M | 255.2M |
— Diluted shares (weighted avg.): No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
— Diluted shares (weighted avg.): No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | RevenueFromContractWithCustomerExcludingAssessedTax | Mar 2017 to Jun 2026 |
|---|---|---|
| Operating income | OperatingIncomeLoss | Mar 2017 to Jun 2026 |
| Net income | NetIncomeLoss | Mar 2017 to Jun 2026 |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Mar 2017 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Mar 2017 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.